Novel actions of sclerostin on bone

Gill Holdsworth, Scott J Roberts and Hua Zhu Ke†
Bone Therapeutic Area, UCB Pharma, Slough, United Kingdom

Correspondence should be addressed to G Holdsworth: Gill.Holdsworth@ucb.com

†(H Z Ke is now at Angitia Biopharmaceuticals, Guangzhou, China)

Abstract
The discovery that two rare autosomal recessive high bone mass conditions were caused by the loss of sclerostin expression prompted studies into its role in bone homeostasis. In this article, we aim to bring together the wealth of information relating to sclerostin in bone though discussion of rare human disorders in which sclerostin is reduced or absent, sclerostin manipulation via genetic approaches and treatment with antibodies that neutralise sclerostin in animal models and in human. Together, these findings demonstrate the importance of sclerostin as a regulator of bone homeostasis and provide valuable insights into its biological mechanism of action. We summarise the current state of knowledge in the field, including the current understanding of the direct effects of sclerostin on the canonical WNT signalling pathway and the actions of sclerostin as an inhibitor of bone formation. We review the effects of sclerostin, and its inhibition, on bone at the cellular and tissue level and discuss new findings that suggest that sclerostin may also regulate adipose tissue. Finally, we highlight areas in which future research is expected to yield additional insights into the biology of sclerostin.

Introduction
One consequence of advances in modern medicine is an ageing global population and a concomitant increase in age-related conditions. Peak bone mass is typically reached in early adulthood, after which, bone quantity and quality decline with advancing years (Riggs & Melton 1986, Boskey & Imbert 2017). Osteoporosis is a prevalent skeletal disorder characterised by reduced bone strength with an associated increased risk of fracture (NIH Consensus Development Panel on Osteoporosis Prevention and Therapy 2001), and approximately 1 in 5 men and 1 in 3 women aged over 50 years will experience a fragility fracture in their remaining lifetime (Cooper & Ferrari 2017). Fragility fractures that occur following low trauma are often the first indication that loss of bone mass and strength has occurred due to dysregulation of the balance between bone formation and bone resorption. Osteoporosis presents a significant burden to the patient and health care systems; hence, there has been great interest in gaining a deeper understanding into the signalling pathways that regulate bone homeostasis.

Insights gained from rare monogenic diseases can identify central pathways and critical nodes involved in tissue homeostasis. Mutations that affect expression of the protein encoded by the SOST gene are found in patients with two very rare high bone mass conditions, highlighting the SOST gene product, sclerostin, as a critical regulator of bone formation and prompting a vast amount of research into its biology. Sclerostin is now understood to act as an antagonist of the canonical WNT signalling pathway in osteoblast lineage cells, thereby negatively regulating bone formation. Inhibition of sclerostin has been proposed as a therapeutic target in bone diseases and
neutalising antibodies to sclerostin (Scl-Ab) have been evaluated in animal models and in clinical trials (reviewed by Lovato & Lewiecki 2017, McClung 2017, Ominskey et al. 2017a, Canalis 2018).

In this review, we summarise the current literature on the biology and mechanism of action of sclerostin in the skeleton and beyond and draw attention to areas in which additional research will further increase our understanding of this fascinating protein.

**Human conditions related to mutation of the SOST gene**

The rare monogenic bone disorders sclerosteosis and van Buchem disease display a recessive Mendelian pattern of inheritance, where the presence of two mutant alleles results in development of the disease phenotype. These closely related conditions were first described in the 1950s (Van Buchem et al., 1955, Truswell 1958) and are caused by different mutations which each affect the SOST gene, causing loss of its protein product, sclerostin. Unlike many osteoporotic high bone mass conditions, which reflect a defect in bone resorption, mutations in SOST are associated with increased bone formation (hyperostosis). Patients with sclerosteosis and van Buchem disease exhibit generalised skeletal sclerosis, leading to increased bone mineral density throughout the skeleton with the greatest prominence at the base of the skull, jaw and long bones (van Lierop et al. 2017). Similarities in the clinical and radiographic features of these patients lead to speculation that the conditions might result from mutations in the same gene and could reflect common ancestry (Brighton et al. 1984). Genome-wide linkage analysis performed in patients with van Buchem disease and sclerosteosis mapped the causative mutation(s) to chromosome 17q12-q21 (Van Hul et al. 1998, Balemans et al. 1999). Subsequently, homozygosity mapping and positional cloning revealed that although these two conditions were indeed caused by mutations that affected the same gene, the genetic lesions underlying each disease were quite distinct in their locations, thus disproving the common ancestor hypothesis. The causative mutations in sclerosteosis and van Buchem disease are discussed in more detail below.

**Sclerosteosis**

Sclerosteosis is predominantly found in the Afrikaner community of South Africa, although a small number of cases have been reported in other countries (van Lierop et al. 2017). Patients are typically of tall stature and syndactyly (fusion of the digits) is often seen and where present, is the earliest postnatal indicator of the disease. Compression of the cranial nerves is frequently present and causes facial palsy and deafness. Thickening of the calvarium can lead to potential lethal elevation of intracranial pressure and this severe clinical manifestation of sclerosteosis is currently managed through complex decompression surgery. Interestingly, the disease is not associated with increased risk of fracture, and the lack of ectopic bone and absence of obvious effects on non-skeletal tissues suggests the defective gene does not have widespread pleiotropic effects. Heterozygous carriers of sclerosteosis have one wild type and one faulty copy of the SOST gene and do not exhibit the profound skeletal phenotype associated with the autosomal recessive disease. However, carriers do have increased bone mineral density (BMD), and levels of circulating sclerostin protein in these individuals are approximately 60% lower compared with controls (van Lierop et al. 2017). In 2001, two groups independently reported loss-of-function mutations in the SOST gene of sclerosteosis patients that result in loss of sclerostin expression due to the presence of a premature stop codon in the amino terminus of the protein (Balemans et al. 2001, Brunkow et al. 2001). Subsequently, additional sclerosteosis-related SOST mutations have been identified, all of which result in the failure to produce active sclerostin protein (van Lierop et al. 2017).

**van Buchem disease**

Van Buchem disease is another rare monogenic autosomal recessive bone sclerosing disorder. Patients with this condition almost invariably originate from an isolated village in the Netherlands and the founder mutation underlying most of these cases has been traced back to 1751 (Van Hul et al. 1998). The skeletal phenotype shares several similarities with sclerosteosis; however, patients tend to be normal height and do not display syndactyly. These differences reflect the divergence of the mutations present in these two conditions. In contrast to the SOST gene mutation found in sclerosteosis, van Buchem patients harbour a 52 kb homozygous deletion of a noncoding enhancer element located 35 kb downstream of the SOST gene, which is required for postnatal expression of sclerostin (Balemans et al. 2002, Loots et al. 2005).
Craniodiaphyseal dysplasia

Craniodiaphyseal dysplasia (CDD) is characterised by facial distortion due to massive generalised hyperostosis and sclerosis of the skull and facial bone. CDD is extremely rare and in this severe disease, increased bone deposition around the craniofacial foramina causes respiratory difficulties that are evident at birth and limit the lifespan of affected individuals. Unlike the recessive inheritance pattern of sclerosteosis and van Buchem disease, the genetic transmission of CDD is not well understood. Two patients with CDD were reported to harbour de novo heterozygous autosomal dominant mutations in SOST that introduced missense mutations in the sclerostin signal peptide cleavage site, preventing secretion of sclerostin protein from transfected cells in vitro (Kim et al. 2011). Interestingly, it was recently reported that endoplasmic reticulum (ER) stress caused by retention of a mutant protein in the osteocyte was associated with a generalised progressive hyperostosis with similarities to CDD (Chan et al. 2017). In this work, expression of a truncated variant of the collagen type X alpha 1 chain (Col10a1) gene in transgenic mice resulted in production of collagen X chains, which were poorly secreted from the cell. Accumulation of this mutant protein promoted ER stress and activation of the unfolded protein response in immature osteocytes, delaying their maturation and increasing the duration of bone formation. Hence, the more severe phenotype observed in the autosomal dominant condition of CDD compared with sclerosteosis and van Buchem disease could reflect a compound effect due to both reduced sclerostin secretion and activation of the unfolded protein response in osteocytes.

WNT signalling

Overview of WNT signalling

Signalling by wingless-related integration site (WNT) proteins represents an evolutionary conserved pathway that has a key role in developmental regulation and adult tissue homeostasis. This ancient signal transduction cascade is found throughout the animal kingdom, including the primitive organisms hydra and sea sponge. In higher mammals, it is immensely complex: in humans there are 19 WNT ligands, each encoded by a separate gene, and there are ten cell-surface frizzled (FZD) receptors and several WNT co-receptors, which direct signalling along one of three distinct intracellular pathways in response to the WNT stimulus. Of these pathways, the canonical WNT-β-catenin pathway is most well studied and is the one upon which sclerostin acts (reviewed by Baron & Kneissel 2013, Nusse & Clevers 2017). The two noncanonical branches of WNT signalling (WNT-planar cell polarity and WNT-calcium) are beyond the scope of this article and will not be discussed further here, however, they have been reviewed elsewhere (Niehrs 2012, Nusse & Clevers 2017).

The intracellular abundance and location of β-catenin provides a central switch in the canonical WNT signalling pathway. Regulation of this pathway has been the subject of much research in the 30 years since the discovery of the first mammalian WNT gene, and a simplified overview which summarises the key components of the canonical WNT-β-catenin signalling pathway in the activated (‘WNT ON’) and basal/inhibited (‘WNT OFF’) states is presented in Fig. 1. The fate of cytoplasmic β-catenin is controlled by the actions of the multi-protein β-catenin-containing destruction complex, in which AXIN and adenomatous polyposis coli (APC) are associated with dishevelled (DVL), β-catenin, casein kinase 1 (CK1) and glycogen synthase kinase 3 beta (GSK3β), which are constitutively active enzymes that phosphorylate β-catenin. Canonical WNT signalling occurs in an autocrine or paracrine fashion and is triggered by binding of WNT ligand to the low-density lipoprotein receptor-related protein 5/6 (LRP5/6) WNT co-receptors and FZD to promote formation of a ternary complex (‘WNT ON’ in Fig. 1), leading to phosphorylation of the cytoplasmic domain of LRP5/6. Interactions between the intracellular regions of LRP5/6 with AXIN, and FZD with DVL, respectively, localise the destruction complex to the cell membrane, inhibiting the activity of the associated kinases. Non-phosphorylated β-catenin accumulates in the cytoplasm and translocates to the nucleus, where it associates with DNA-bound T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors to initiate transcription of WNT target genes.

In common with other morphogenic pathways, tight control of WNT pathway activation is required, and one way in which this is achieved is via the existence of multiple secreted antagonists. These may be subdivided into broad classes: those that bind WNT ligands or those that bind WNT co-receptors. Sclerostin falls into the latter category. In the basal or sclerostin-inhibited state (‘WNT OFF’ in Fig. 1), β-catenin is constitutively produced and degraded through the actions of the destruction complex. Phosphorylation of β-catenin by CK1 and GSK3β labels it for ubiquitination and proteasomal degradation, preventing its accumulation and nuclear translocation. In the absence of nuclear β-catenin, TCF/LEF is associated
with the transcriptional repressor Groucho and is maintained in an inactive state.

**Canonical WNT signalling in bone**

Recognition of the importance of the canonical WNT pathway as a regulator of bone mass came through the discovery of mutations in the LRPS WNT co-receptor that were associated with altered bone density. Loss-of-function mutations were described in patients with the low bone mass condition osteoporosis pseudoglioma (OPPG) (Gong et al. 2001) whilst missense mutations in the extracellular domain were found in patients with high bone mass (Van Wesenbeeck et al. 2003, Little et al. 2017). Canonical WNT signalling promotes bone formation through its effects on mesenchymal stem cells (MSC) and activation of the pathway promotes commitment to, and differentiation towards, the osteoblastic lineage whilst inhibiting adipogenic and chondrogenic commitment (reviewed by Baron & Kneissel 2013, Lerner & Ohlsson 2015). In addition to favouring bone formation, canonical WNT signalling also decreases bone resorption by increasing expression of the WNT target gene osteoprotegerin (OPG), which acts as a decoy receptor for receptor activator of nuclear factor-κB ligand (RANKL) to inhibit osteoclastogenesis (Glass et al. 2005).

**Sclerostin**

**Expression**

Sclerostin is expressed in the mouse limb bud and skeletal anlage during embryogenesis (Loots et al. 2005), and its involvement with limb patterning in mice is consistent with the syndactyly reported in some sclerosteosis patients (Collette et al. 2016). In the adult, expression is largely restricted to the skeleton where it is produced by mature osteocytes but not by early osteocytes, osteoblasts or bone lining cells (Poole et al. 2005). Sclerostin is expressed at lower levels in other cells associated with mineralised matrix, including cementocytes, hypertrophic and articular chondrocytes, as well as synovial fibroblasts.

**Figure 1**

A simplified overview of the canonical WNT signalling pathway, and its inhibition by sclerostin. In the WNT ON state, extracellular WNT ligands bind the LRPS/6 cell surface receptor and a frizzled (FZD) family cell-surface receptor to form a ternary complex, leading to translocation of the destruction complex to the cell membrane, phosphorylation of the intracellular region of LRPS/6 and recruitment of AXIN which disrupts destruction complex activity. Non-phosphorylated β-catenin accumulates in the cytoplasm and translocates to the nucleus where it binds the TCF/LEF transcription factors to initiate transcription of WNT target genes. In the WNT OFF (sclerostin inhibited) state, sclerostin (Scl) binds to the LRPS4 and LRPS/6 cell-surface receptors, preventing the interaction between WNT ligands with LRPS/6. This prevents formation of the LRPS/6–WNT–FZD ternary complex and hence inhibits canonical WNTsignalling. Cytosolic β-catenin is phosphorylated and targeted for ubiquitination by the destruction complex and degraded in the proteasome. TCF/LEF transcription factors in the nucleus are associated with Groucho and WNT target gene transcription is repressed. This figure was produced using Servier Medical Art.
(Chouinard et al. 2016, Wehmeyer et al. 2016). In mice, Sost mRNA is expressed in vascular smooth muscle cells of the great arteries during embryonic and neonatal development (van Bezooijen et al. 2007) whilst sclerostin protein is present in human aorta (Didangelos et al. 2010, Krishna et al. 2017). Its expression is upregulated in the foci of vascular calcification (Zhu et al. 2011, Zhou et al. 2017), where it has been proposed as a potential regulator of mineralisation.

Expression of sclerostin in osteocytes is inversely related to mechanical loading in vivo and in ex vivo bone explant cultures (Robling et al. 2008, Kogawa et al. 2018), in line with the proposed role of the osteocyte as a skeletal mechanosensor. SOST mRNA was expressed at similar abundance in bone biopsies collected from young (22–44 years) and old (64–88 years) women, indicating that bone sclerostin mRNA levels do not increase with age (Roforth et al. 2014). Apart from sclerosteosis patients, in whom it is not detected, sclerostin protein is present in the circulation and its levels are reported to increase with age (Roforth et al. 2014, van Lierop et al. 2017). Immobilisation is associated with decreased BMD and increased serum sclerostin in animal models and humans (Robling et al. 2008, Clarke & Drake 2013, Spatz et al. 2013).

The consequences of sclerostin overexpression have been investigated in rodents. Liver-directed adeno-associated viral (AAV) was used to systemically overexpress sclerostin in mice and increased serum sclerostin by approximately 65%, resulting in modest reductions in femoral and vertebral trabecular bone fraction (Kim et al. 2017a). Similarly, long-term liver expression of exogenous sclerostin following hydrodynamic transfection resulted in approximately two-fold higher serum sclerostin concentration and a small reduction in trabecular bone fraction in the tibia (Zhang et al. 2016). Whilst these findings suggest that systemic sclerostin may contribute to skeletal homeostasis, the relevance of circulating sclerostin on the skeleton is not fully understood. The actions of sclerostin within the skeleton are thought to reflect the local activity of the protein following its release from osteocytes (Poole et al. 2005). Circulating sclerostin does not always correlate with bone density and mutations in the LRP4 sclerostin co-receptor which impair sclerostin binding are associated with significantly increased circulating sclerostin and increased bone mass (Fijalkowski et al. 2016).

Extracellular vesicles (EV) are nanoscale membrane vesicles released from cells. They are categorized by size and the manner of their release: exosomes (less than 150nm in diameter) arise from fusion of late endosomes with the plasma membrane, whilst microvesicles and apoptotic bodies are typically at least 100nm in diameter and are released directly from the plasma membrane (Hessvik & Llorente 2018). Exosomes are believed to facilitate intercellular communication and have been the subject of much research in recent years. Osteocytes release EV in vivo (Wang et al. 2017). The quantity of EVs released and their composition may reflect cellular conditions and ex vivo studies on intact bones subjected to mechanical stimulation found that osteocyte EV release is upregulated in a calcium-dependent manner (Morrell et al. 2018). Importantly, EV released from osteocyte cell lines contain regulatory proteins including RANKL, OPG and sclerostin (Wang et al. 2017, Morrell et al. 2018), suggesting this mechanism may represent part of the skeletal response to mechanical load.

### Biochemistry and structure

Following discovery of the SOST gene, analysis of the 213 long primary amino acid sequence of its protein product identified sclerostin as a potential new member of the Dan/Cerberus family of bone morphogenetic protein (BMP) antagonists (Brunkow et al. 2001). In common with other family members, sclerostin is a secreted glycoprotein that contains a cysteine knot motif, however, unlike the prototypical BMP antagonists, it lacks free cysteine residue which mediates dimerization in other examples of this protein class. Sclerostin contains two potential N-linked glycosylation sites, which are conserved across species, and it contains many positively charged lysine and arginine residues, giving it a predicted isoelectric point (pI) of approximately 9.5. Expression in mammalian systems yields a mature 190 amino acid protein, which runs as a doublet on SDS-PAGE (Krause et al. 2010, Holdsworth et al. 2012), likely reflecting differences in the extent of glycosylation. The functional significance of this post-translational modification is unclear since protein produced in E. coli was shown to be similarly effective in a WNT reporter assay compared with sclerostin produced in mammalian systems (Veverka et al. 2009).

Structural studies revealed sclerostin exists in solution as a highly flexible monomer comprising ordered and disordered regions (Veverka et al. 2009, Weidauer et al. 2009). The principal features of the sclerostin structure include N- and C-terminal arms, which are disordered in the free solution state, and three loops which are formed around the cysteine knot motif. The so-called loops 1 and 3 have the cysteine knot at their base and their tips are...
Interactions with cell-surface receptors and glycosaminoglycans

Sclerostin binds the first beta propeller (E1) of the LRPS/6 WNT co-receptors to inhibit canonical WNT signalling (Li et al. 2005, Semenov et al. 2005, Holdsworth et al. 2012). The LRPS/6 extracellular domain contains four beta propellers and WNT ligands can be subcategorised based on their interaction with these propellers. WNT1 class ligands bind propeller 1 (E1) whilst the WNT3a class binds propeller 3 (E3) (Bourhis et al. 2010, Ettenberg et al. 2010). Consistent with this, sclerostin preferentially inhibits WNT1 class canonical signalling or binding (Bourhis et al. 2011, Holdsworth et al. 2012). In contrast, the Dickkopf (Dkk) family of WNT antagonists can bind E1 or E3 and thus inhibit both WNT1 and WNT3a class signalling (Bourhis et al. 2010, Patel et al. 2018). The existence of propeller-selective WNT antagonists may provide an additional level of fine tuning to regulate the Wnt signalling.

High-affinity binding of sclerostin to LRPS/6 is dependent on the conserved ‘NxI’ motif found in loop 2 of sclerostin (shown in Fig. 2), in which an asparagine (N) and an isoleucine (I) residue are separated by any amino acid (x). Mutation of the N or I position significantly reduced the efficacy of sclerostin as an inhibitor in a WNT-stimulated reporter assay (Bourhis et al. 2011, Holdsworth et al. 2012). The interaction of loop 2 with the first propeller of LRPS/6 is essential for inhibition of WNT signalling, however, several observations imply the existence of additional contacts between sclerostin and LRPS/6. Firstly, sclerostin binds approximately 10-fold more strongly to a purified protein containing the first and second beta propellers of LRPS (E1E2) than to LRPS E1 alone (Bourhis et al. 2011). Secondly, cyclic peptides derived from loop 2 of sclerostin bind LRPS E1 or E1E2 with similar affinity; however, this interaction is approximately two orders of magnitude weaker compared...
with the binding of full-length sclerostin to the same LRP6 protein (Bourhis et al. 2010, Holdsworth et al. 2012). Together, these data suggest that currently unidentified regions outside of loop 2 may participate in additional interactions with E2 of LRP5/6 and contribute to binding affinity.

Sclerostin also binds to the related LRP4 receptor. Despite its structural similarity with LRP5/6, LRP4 is not recognised as a Wnt co-receptor; instead, it is proposed to act as a sclerostin co-receptor since its overexpression enhances the efficacy of sclerostin in cell-based Wnt reporter assays whilst LRP4 silencing reduces sclerostin’s function (Leupin et al. 2011). Mutations in LRP4 are found in patients with sclerosteosis 2 – another very rare high bone mass disorder that bears many similarities to those diseases in which sclerostin itself is lacking (Leupin et al. 2011, Fijalkowski et al. 2016). The causative mutations in the third propeller (E3) of LRP4 are associated with impaired sclerostin binding (Leupin et al. 2011). Interestingly, the failure of sclerostin to bind LRP4 – either through the presence of LRP4 high bone mass mutations or following administration of an antibody directed against LRP4 – is associated with increased serum sclerostin (Chang et al. 2014, Fijalkowski et al. 2016), suggesting LRP4 acts as an anchor to retain sclerostin in the skeleton. The ability of distinct sclerostin antibodies to differentially block binding to LRP4 and/or LRP6 has given some insights into the mechanism of the sclerostin-LRP4 interaction and suggests that sclerostin loop 2 is not critical for binding LRP4 (Holdsworth et al. 2012, Gong et al. 2016).

Sclerostin was originally posited as a potential modulator of BMP pathway signalling (Brunkow et al. 2001). Interactions between sclerostin and various BMP ligands, which result in diminished BMP receptor signalling have been reported (Winkler et al. 2003, Krause et al. 2010); however, these effects have not been extensively studied and do not appear to represent the principal actions of sclerostin on the skeleton so will not be discussed in depth here.

Structural studies of sclerostin revealed the presence of a heparin-binding patch, which is formed from a linear region of positively charged amino acids in loops 2 and 3, which covers one side of the protein and promotes a functional association between sclerostin and heparin that localises sclerostin to the surface of transfected cells (Veverka et al. 2009). More recently, this area was identified as a common binding region for various sulphated glycosaminoglycans (GAGs), which interfere with the interaction between sclerostin and LRP5/6 and restore WNT signalling in a reporter cell line (Salbach-Hirsch et al. 2015). GAGs are long unbranched polysaccharide molecules that are present as heparan sulphate proteoglycans within the extracellular matrix of bone. Hence, the binding of sclerostin to cell surface and bone matrix GAGs may contribute to the local regulation of sclerostin function.

Sclerostin inhibition of canonical WNT signalling

The discovery that sclerostin bound the LRP5/6 WNT co-receptors to antagonise canonical WNT signalling came when the critical connection was made between the high bone mass (HBM) phenotype associated with the absence of sclerostin and similar phenotypes resulting from HBM mutations in LRP5 (Li et al. 2005, Semenov et al. 2005). The previously reported HBM mutations are all located in LRP5 E1 and helped identify the region of LRP5/6 to which sclerostin binds (Van Wesenbeeck et al. 2003, Little et al. 2017) since they impair sclerostin binding, thus preventing its action as a WNT inhibitor (Semenov & He 2006). Subsequently, monoclonal antibodies which bind sclerostin and inhibit its interaction with LRP4/5/6 have been developed as a therapeutic strategy to increase bone mass and strength in osteoporosis and other low bone mass conditions. This topic is discussed in more depth later in this article, and has also been the subject of several recent reviews (Lovato & Lewiecki 2017, McClung 2017, Canalis 2018).

Cellular level actions of sclerostin revealed from in vitro and in vivo studies

Since the discovery of sclerostin almost 20 years ago, a wealth of published data has described its actions at the cellular level, using in vitro model systems and in vivo studies. A range of approaches has been used, including sclerostin introduction (via treatment with recombinant sclerostin protein or overexpression of sclerostin in transgenic animals), sclerostin deletion (using animals null for the Sost gene) and neutralisation of endogenous sclerostin using Scl-Ab. The dual effects of sclerostin as a potent inhibitor of bone formation and a regulator of bone resorption have thereby emerged. Figure 3 summarises the cellular level actions of sclerostin, which are discussed in detail in the following sections.
Osteoblast lineage

Sclerostin directly modulates the osteoprogenitor population and regulates osteoblast lineage function. The specific action of sclerostin as an inhibitor of canonical WNT signalling was demonstrated in the mouse pre-osteoblast cell lines transfected to express a luciferase reporter of the canonical WNT pathway (Veverka et al. 2009, Krause et al. 2010). In vitro, sclerostin inhibits cell proliferation, decreases alkaline phosphatase activity and mineralisation and increases apoptosis in osteogenic cultures of mouse and MSC or human primary osteoblasts (Winkler et al. 2003, Sutherland et al. 2004, Atkins et al. 2011). Likewise, alkaline phosphatase expression and mineralisation are reduced in ex vivo cultures of MSC or primary osteoblasts from transgenic mice engineered to overexpress sclerostin, compared with cells from WT littermate controls (Winkler et al. 2003, Yorgan et al. 2015). Conversely, inhibition of sclerostin is associated with restoration of WNT signalling, and cultures of MSCs collected from mice treated with Scl-Ab show enhanced osteogenesis compared with cells from control mice (Veverka et al. 2009, Shahnazari et al. 2012). The phosphate-regulating neutral endopeptidase, X-linked/ matrix extracellular phosphoglycoprotein (PHEX/MEPE) axis is involved in regulating the mineralisation of newly formed bone. Sclerostin-mediated inhibition of osteoblast mineralisation in human primary cells or bovine bone explants is associated with upregulation of the mineralisation inhibitor MEPE and a concomitant decrease in expression of the pro-mineralisation enzyme PHEx (Atkins et al. 2011, Kogawa et al. 2018).

Insights into sclerostin’s action as a regulator of osteoprogenitor differentiation, recruitment and mineral apposition have come from rodent studies using Scl-Ab. Lineage tracing experiments show that Scl-Ab increases the number of osteoprogenitor cells by increasing proliferation and decreasing apoptosis, thus indicating that sclerostin represses osteoprogenitor differentiation (Trinh et al. 2017). Neutralisation of sclerostin enhances proliferation and recruitment of osteoprogenitor cells to active surfaces, increases bone formation and osteoblast number and elevates ‘osteoblast vigour’, leading to increased bone formation per osteoblast (Ominsky et al. 2015, Taylor et al. 2016, Greenbaum et al. 2017, Boyce et al. 2018). The inactive surfaces of bone are occupied by bone lining cells (BLC), which arise from active osteoblasts that have neither undergone apoptosis nor embedded into newly mineralised matrix as osteocytes. Despite their abundance, these cells are a poorly studied population, and it has not yet been possible to culture BLC in vitro. Elegant in vivo lineage-tracing studies performed in mice highlighted BLC as a pool of precursors that are rapidly reactivated into active osteoblasts on periosteal and endocortical surfaces following treatment with Scl-Ab (Kim et al. 2017b), indicating that sclerostin inhibition of
WNT signalling contributes to the maintenance of BLC in a quiescent state.

The transition of late osteoblasts to early osteocytes is inhibited in vitro by sclerostin, suggesting a role for sclerostin as a regulator of osteocyte maturation (Atkins et al. 2011). The study of sclerostin biology in osteocytes is challenging and the nature of the osteocyte means it is best studied as a cell within its lacuna, surrounded by its native 3D mineralised environment. Isolation and culture of primary osteocytes from bones is technically difficult and typically yields few viable cells, whilst the few immortalised osteocyte cell lines currently available show variable sclerostin expression. The early osteocyte cell lines, MLO-Y4 and MLO-A5 were derived from a transgenic mouse, which expressed large T-antigen under the control of the osteocalcin promoter (Kato et al. 1997, Kato et al. 2001). Sclerostin is a late osteocyte marker and is not highly expressed in MLO-Y4 and MLO-A5 cells. Two additional cell lines, IDG-SW3 and Ocy454, were isolated from double transgenic mice expressing green fluorescent protein (Gfp1) under the dentin matrix acidic phosphoprotein 1 (Dmp1) promoter as well as a thermolabile large T-antigen. Importantly, both cell lines resemble late osteocytes and hence express high levels of late osteocyte markers, including sclerostin (Woo et al. 2011, Spatz et al. 2015). Ex vivo bone explants have the advantage of allowing the study of living osteocytes within their natural setting and are particularly well suited to investigating the response to mechanical loading (Kogawa et al. 2018, Morrell et al. 2018). More recently, advances have been made in the 3D culture of osteocytes using biomimetic assemblies, which allow formation of an inter-osteocyte connection network that replicates mecanoostransduction responses (Sun et al. 2017, 2018). Since sclerostin expression is regulated by mechanical loading, access to such systems, which more faithfully reproduce the osteocyte’s native environment, will prove highly useful in the future.

Sclerostin is a regulator of osteocyte apoptosis. In vivo, loss of Sost leads to enhanced canonical WNT signalling and decreased apoptosis in osteocytes (Lin et al. 2009, Krause et al. 2010). Focal radiation-induced DNA damage increases sclerostin expression in the locality of the irradiated area. Inhibition of sclerostin in a mouse model of radiation damage protected osteoblasts from apoptosis through activation of canonical WNT signalling (Chandra et al. 2017). The role of sclerostin in osteocyte apoptosis following exposure to glucocorticoids is less well understood and contrasting outcomes following the inhibition or absence of sclerostin have been reported. In one mouse model, Scl-Ab prevented the decrease in lacunae occupancy and increase in osteocyte apoptosis caused by exogenous glucocorticoids (Achiou et al. 2015) whilst in a different model, genetic deletion of Sost did not reduce glucocorticoid-induced osteoblast/osteocyte apoptosis (Sato et al. 2016). These divergent outcomes may reflect differences in the models used, or the method of sclerostin inhibition, or could suggest that other factors besides sclerostin are involved in regulating osteocyte apoptosis.

The ability of osteocytes to resorb mineral in their locality is termed ‘osteocytic osteolysis’. Although this remains a somewhat controversial topic, studies in lactating animals suggest that osteocytes may be able to remove the perilacunar matrix thereby mobilising calcium (reviewed by Qing & Bonewald 2009, Prideaux et al. 2016, Kovacs 2017). Sclerostin has been reported to upregulate expression of several proteins involved in this process. Treatment of primary human osteocyte-like cells or mouse MLO-Y4 cells with sclerostin increased expression of transcripts encoding carbonic anhydrase 2 (Ca2), cathepsin K (Ctsk) and tartrate-resistant acid phosphatase form 5b (Acps) in an LRP4/5/6-dependent manner whilst addition of sclerostin to ex vivo explant cultures of human cancellous bone increased lacunar size (Kogawa et al. 2013). Furthermore, studies conducted using bovine trabecular bone explants showed similar effects on expression of genes related to matrix catabolism and additionally demonstrated release of the C-terminal collagen telopeptide, β-CTx, which is indicative of collagen breakdown and is consistent with lacunar enlargement following exposure to recombinant sclerostin (Kogawa et al. 2018). Hence, sclerostin may contribute to the regulation of perilacunar mineral by resident osteocytes.

The importance of sclerostin in the maintenance of osteocyte morphology and connectivity is indicated from studies using genetic or antibody approaches. Mice lacking the matricellular protein periostin display increased sclerostin expression and round-shaped osteocytes with decreased dendrite number and length. Restoration of osteocyte morphology to a well-connected spindle-like morphology was observed when the Sost gene was deleted or Sci-Ab was used to neutralise sclerostin function (Ren et al. 2015). In other models, where osteocyte number (lacuna occupancy), morphology and connectivity are profoundly affected, including spinal cord injury and focal radiation-induced DNA damage, absence of sclerostin or Sci-Ab treatment preserved osteocyte number, morphology and orientation (Qin et al. 2015, Chandra et al. 2017). Interestingly, in models of
mechanical unloading, expression of sclerostin is increased in individual osteocytes; however, the proportion of sclerostin-positive osteocytes is not changed (Lloyd et al. 2013) and inhibition of sclerostin by Scl-Ab does not alter osteocyte density (Qin et al. 2015).

Together, these findings indicate that the action of sclerostin as an inhibitor of bone formation is achieved throughout the osteoblast lineage: control of osteoprogenitor cell proliferation and recruitment, inhibition of osteogenic commitment and differentiation, negative regulation of osteoblast activity, maintenance of bone lining cell quiescence, suppression of late osteoblast differentiation into osteocytes and regulation of osteocyte longevity, shape and connectivity.

**Osteoclasts**

Whilst sclerostin does not appear to directly regulate the differentiation or activity of osteoclasts, studies of cells obtained from animals deficient in sclerostin or treated with Scl-Ab provide evidence that sclerostin does have important indirect effects on the osteoclast lineage. The binding of RANKL to its cognate receptor, receptor activator of nuclear factor-κB (RANK) on osteoclast precursors promotes osteoclastogenesis. RANKL activity is negatively regulated by the decoy receptor, OPG, hence the RANKL:OPG ratio is a key determinant of osteoclastogenesis. The importance of osteoblast-specific canonical WNT signalling on osteoclast differentiation has been demonstrated through manipulation of β-catenin in mice where osteoblast-specific pathway activation increased expression of the WNT target gene Opg, leading to reduced resorption whilst deletion of β-catenin in osteoblasts concomitantly decreased Opg expression and promoted higher resorption (Glass et al. 2005). Osteocyte-specific activation of β-catenin also increased Opg, but in contrast to the effects in osteoblasts, Rankl expression and bone resorption were also increased. The increased Rankl expression was sclerostin-dependent since it was reversed by Scl-Ab whilst sclerostin overexpression in osteocytes enhanced Rankl expression in these cells (Tu et al. 2015). Therefore, inhibition of canonical WNT signalling by sclerostin in osteocytes would be expected to promote bone resorption.

Addition of recombinant sclerostin to in vitro cultures of the osteocyte MLO-Y4 cell line or human pre-osteocytes increased the RANKL:OPG ratio by upregulating Rankl expression and downregulating Opg. In co-cultures with mouse splenocytes or human PBMCs, sclerostin enhanced osteoclastogenesis and elevated resorption in a RANKL-dependent manner; however, addition of sclerostin to splenocyte or PBMC monocytes had no effect on osteoclastogenesis, indicating that sclerostin does not directly influence these cells (Wijenayaka et al. 2011). Osteoblast lineage cells from rats treated with Scl-Ab show decreased RANKL:OPG ratio, largely as a result of elevated Opg expression (Taylor et al. 2016) and in agreement with this, fewer TRAP5b-positive osteoclast-like cells are obtained in cultures of osteoclast progenitors collected from rats following treatment with Scl-Ab (Stolina et al. 2014).

In addition to its effects on the RANKL:OPG ratio, there is evidence that sclerostin can affect the expression of other positive and negative regulators of osteoclastogenesis. Antibody-mediated sclerostin neutralisation in vivo decreased the abundance of mRNAs encoding colony stimulating factor 1 (Csf1) and increased WNT1-induced secreted protein 1 (Wisp1) abundance in osteoclast-lineage cells (Taylor et al. 2016, Holdsworth et al. 2018), suggesting two potential additional indirect axes through which sclerostin could regulate osteoclastogenesis.

**Chondrocytes**

Differentiation of MSCs into chondrocytes is inhibited when canonical WNT signalling is activated. The effect of sclerostin on chondrocytes is relatively poorly studied; however, it is known that the protein is expressed by hypertrophic chondrocytes in the growth plate and by articular chondrocytes (Winkler et al. 2003, van Bezooijen et al. 2009, Chan et al. 2011). In vitro, sclerostin inhibits chondrocyte apoptosis and promotes a cartilage homeostatic phenotype by decreasing expression of catabolic proteases and increasing anabolic gene expression (Chan et al. 2011, Bouaziz et al. 2015). In vivo, sclerostin is expressed in the articular cartilage of rodents and humans; however, contradictory reports exist on the role of sclerostin in articular cartilage remodelling. Genetic loss of sclerostin (Sost KO) in mice does not alter articular cartilage formation, whilst its loss does appear to aggravate the development of osteoarthritis (OA) in mice subjected to joint instability (Bouaziz et al. 2015). Conversely, Roudier et al. (2013) reported that the absence of sclerostin does not alter the development of age-related OA in mice and that antibody-mediated neutralisation of sclerostin has no impact on cartilage remodelling in a rat model of post-traumatic OA. Interestingly, a recent report detailed the beneficial effect that exogenous sclerostin may have on the progression of post-traumatic OA. Indeed, Sost transgenic mice develop a less severe
phenotype than WT or Sost KO mice, and intra-articular administration of recombinant sclerostin to WT mice reduces the level of activated MMPs (Chang et al. 2018). These reports highlight specific differences in the biology observed when considering the effect of genetic deletion/overexpression of sclerostin vs pharmacological inhibition.

Adipocytes

Adipose tissue exists in multiple anatomical locations, most of which are outside of the skeleton; however, bone has been shown to influence global energy metabolism through release of endocrine factors such as osteocalcin by osteoblast lineage cells (reviewed by Wei & Karsenty 2015, Suchacki et al. 2017). The concept that sclerostin and energy metabolism could be linked reflects several observations including positive associations between serum sclerostin and metabolic parameters such as fat mass and type 2 diabetes (Amrein et al. 2012, Clarke & Drake 2013). In addition, LRPS HBM mutations have been linked with regulation of body fat distribution (Loh et al. 2015), highlighting the importance of canonical WNT pathway activity on adipose progenitors. The three main types of adipose tissue – white adipose tissue (WAT), brown adipose tissue (BAT), bone marrow adipose tissue (BMAT) – reside in distinct anatomical locations and have non-overlapping physiological functions. WAT functions as an energy store and is the major component of the subcutaneous and visceral fat depots. Both WAT and BAT have an endocrine function and release adipokines, which regulate global energy metabolism. The primary role of BAT is thermoregulation; this adipose depot is found at low levels in adult and is characterised by expression of the uncoupling protein 1 transcript (Ucp1). Although BAT and WAT arise from different progenitors, WAT can gain expression of Ucp1 to become ‘beige’ adipose, which is functionally similar to BAT. BMAT is thought to arise from mesenchymal progenitors within the bone marrow cavity and is emerging as an additional active adipose depot that is functionally distinct from WAT and BAT and is highly linked to metabolic status and bone mass (Fairfield et al. 2017b).

Recent work performed in rodent models has identified a potential new role for sclerostin in adipose tissue regulation, as summarised in Figure 4. Consistent with the increase in circulating sclerostin in type 2 diabetes in humans, mice fed a high-fat diet display increased body weight and fat mass, develop metabolic disease and have elevated serum sclerostin (Kim et al. 2017a). In vitro, sclerostin inhibition of WNT signalling in MSCs or preadipocytes promotes adipogenesis whilst in vivo, Sost-null mice display reduced WAT that contains smaller adipocytes compared with WAT from WT controls, whilst Scl-Ab partially reduced the weight gain and size of WAT deposits in mice fed a high-fat diet (Kim et al. 2017a). Together, these findings indicate that sclerostin neutralisation prevents accumulation of white adipose tissue mass. Sost-null mice exhibit increased expression of the beige marker, Ucp1, in WAT depots compared to WT littermates, suggesting sclerostin can regulate browning of white adipocytes. Interestingly, the amount of BAT in the interscapular depot did not differ in Sost-null mice compared with their WT littermates, which may reflect a lesser effect of sclerostin on constitutive brown adipose (Kim et al. 2017a).

Early in life, BMAT (also referred to as ‘yellow marrow’) starts to form in the bone marrow cavity. The extent of this adipose-rich tissue increases with age and its formation progresses from the extremities of the appendicular skeleton towards the centre of the body. The BMAT depot is less well understood than BAT or WAT, and its influence on the skeleton is the subject of intense interest since its anatomical location means it is ideally placed to provide a fat-bone connection. BMAT is elevated in conditions associated with low bone mass, including osteoporosis, anorexia nervosa, ageing and chronic kidney disease (CKD) (Hardouin et al. 2016, Fairfield et al. 2017b, Woods et al. 2018). In mice, absence of sclerostin...
is associated with decreased BMAT whilst Scl-Ab reduces BMAT accumulation by decreasing both adipocyte number and size (Fairfield et al. 2017b). In humans, the severity of CKD was recently reported to be associated with increases in both BMAT as well as serum sclerostin, which may suggest sclerostin contributes to BMAT in patients with CKD (Woods et al. 2018). Additional studies are required to investigate the role of sclerostin in BMAT regulation.

Sclerostin therefore participates in crosstalk between the skeleton and adipose tissue, acting as an endocrine factor to enhance adipogenesis in WAT and promote MSC differentiation towards the adipogenic lineage within bone marrow. Although the effect of LRP5 mutations on adipose progenitors and body fat distribution in humans has been reported, the translation of mutations affecting the SOST gene or sclerostin inhibition on adipogenesis and fat depot-specific regulation to humans is currently unknown.

**Sclerostin as a regulator of bone mass and strength**

The first preclinical evidence of sclerostin’s negative effects on bone formation, mass and strength was reported using Sost transgenic mice that overexpress sclerostin. Reduced trabecular bone volume, cortical bone thickness, decreased bone strength due to significantly reduced bone formation and a non-significant change in bone resorption were observed in Sost transgenic mice compared with WT controls (Winkler et al. 2003). In contrast to the transgenic mice, Sost-knockout (KO) mice were shown to rapidly increase BMD in lumbar spine and long bones up to 4 months of age, after which lumbar spine BMD was maintained at the elevated level through 18 months of age, whilst there was a more gradual but continuous increase in long bone BMD in the same time frame (Ke et al. 2012). The bone phenotype in Sost KO mice reproduced the sclerosteosis phenotype as described above. Bone formation parameters were increased on trabecular, periosteal and endocortical surfaces, whilst no significant change was observed in serum markers of bone resorption or osteoclast surface area in the Sost KO mice compared with controls.

The results from these genetic manipulation studies in mice confirmed that sclerostin is indeed a negative regulator of bone mass and bone strength via the inhibition of bone formation *in vivo*. These data led to the hypothesis that pharmacological inhibition of sclerostin may deliver benefit to patients suffering from conditions of low bone mass and increased risk of fragility fractures, such as osteoporosis, through the induction of an increase in bone formation, mass and strength. Several Scl-Abs have been generated and tested for their efficacy in preclinical models and in patients with low bone mass and/or poor bone quality. It appears that the bone formation response to Scl-Ab treatment can be separated into two phases: an initial transient phase and a steady phase that persists with longer-term treatment. During the transient phase, Scl-Ab significantly and rapidly increases modelling-based bone formation by activating bone lining cells to become bone-forming osteoblasts, increasing osteoblast activity and recruitment and reducing osteoblast apoptosis (Ominsky et al. 2017a). However, after the transient phase, bone formation returns towards the baseline level despite continuous treatment with Scl-Ab. The mechanism for this steady phase effect on bone formation is a topic of continued investigation. A rapid increase in bone mass during the transient phase may lead to a reduction in local micro-strain on bone surface, thus activating negative feedback mechanisms to control bone formation. Upregulation of WNT antagonists including sclerostin and DKK1 and normalisation of some WNT target genes may contribute to the self-regulation of bone formation during the steady phase of treatment (Taylor et al. 2016, Holdsworth et al. 2018). During the steady phase, Scl-Ab increased wall thickness and decreased resorption depth leading to a positive bone balance in the remodelling unit (Boyce et al. 2017). As mentioned above, Scl-Ab treatment also reduces osteocyte apoptosis and restores osteocyte morphology and connectivity in disease models that affect osteocytes (Achiou et al. 2015, Qin et al. 2015, Ren et al. 2015), although the contribution of these effects on bone formation and resorption requires further investigation. While the effect of Scl-Ab on bone resorption in preclinical models has been either no significant change or significant decrease, depending on the baseline bone resorption activities (see review by Ominsky et al. 2017a), results from clinical trials have consistently demonstrated that Scl-Ab significantly decreased serum markers of bone resorption during the transient phase and maintained at the decreased level in the steady phase (McClung et al. 2014, Cosman et al. 2016). Histomorphometric analysis of bone biopsies from clinical trials of Scl-Ab indicates that sclerostin inhibition produces an early, significant bone-forming effect and a sustained reduction in bone resorption (Chavassieux et al. 2017).

Studies in rodent models have permitted the comparison of tissue-level outcomes following antibody-mediated inhibition of sclerostin, as well as genetic deletion or transgenic overexpression of Sost, and...
overexpression of recombinant sclerostin by the liver. Table 1 summarises these findings.

The rapid bone gain induced by Scl-Ab treatment leads to a significant increase in bone strength while maintaining bone quality in the osteoporosis animal models of OVX rats and OVX cynomolgus monkeys with 12 months of treatment (Ominsky et al. 2017a,b). The clinical translation of these preclinical data has been demonstrated in postmenopausal osteoporosis, osteoporosis in men and other conditions with low bone mass and poor bone quality. Much of the clinical data have come from trials of Scl-Ab in patients with osteoporosis and are summarised in several recent reviews (Lovato & Lewiecki 2017, McClung 2017, Canalis 2018).

The data from preclinical animal studies as well as clinical trials in patients with low bone mass and increased risk of fragility fracture confirm that sclerostin is a negative regulator of bone formation, bone mass and bone strength. Experimental data also show that inhibition of sclerostin with Scl-Ab stimulates bone formation, decreases bone resorption, increases bone mass and strength and reduces the risk of fragility fractures.

The involvement of sclerostin in other human disease: multiple myeloma

Multiple myeloma (MM) is a plasma cell (differentiated B lymphocyte) cancer, characterised by extensive proliferation of transformed cells in the bone marrow. Bone disease is a devastating complication of MM caused by a deregulation of the cellular determinants of bone homeostasis, resulting in bone loss, osteolytic lesions, bone pain and increased fracture risk (Hameed et al. 2014). WNT signalling has been associated with MM through the identification of the WNT antagonist DKK1 as a potential mediator of molecular crosstalk between MM cells and osteoblasts (Tian et al. 2003). In addition to KK1, sclerostin has also been implicated in MM where patients with active myeloma display increased levels of circulating sclerostin, which correlates with severe bone disease (Terpos et al. 2012). Recently, it has been reported that DKK1 and sclerostin may be early markers of relapse in MM, as a significant increase in serum concentrations of both proteins are observed prior to relapse (Mabille et al. 2018).

The source of sclerostin in MM is controversial, with several publications claiming expression and secretion from MM cells (Brunetti et al. 2011, Colucci et al. 2011, Habibi et al. 2013, Wang et al. 2014). Conversely, a study detailing the expression profile in a cohort of 630 MM patients described no difference in MM bone marrow plasma cell expression of SOST compared to healthy controls (McDonald et al. 2017). Perhaps a more plausible mechanism to explain the elevated sclerostin in MM patients reflects interaction of the MM tumour directly with bone cells in the tumour microenvironment. Indeed, it has been reported that osteocytes in contact with MM cells express high levels of sclerostin in vitro (Delgado-Calle et al. 2016). This subsequently causes a downregulation of local WNT signalling and inhibition of osteoblast differentiation. Sclerostin expression is evident in marrow stromal cells and osteoblasts within MM patient bone marrow samples, and MM cells can induce sclerostin expression in immature osteoblasts in vitro, which has the capacity to subsequently inhibit osteoblast differentiation. Interestingly, expression of Sost appears to be regulated by MM cell-derived DKK1 (Eda et al. 2016). MM cells also appear to increase the number of sclerostin-positive osteocytes in cortical and trabecular bone in murine models (Delgado-Calle et al. 2017), thus giving rise to another potential explanation for elevated circulating sclerostin in MM patients.

Consequently, sclerostin has become a pharmacological target in MM research. In preclinical murine models, treatment with Scl-Ab antibody reversed myeloma bone disease through induction of

| Sost null | ↑↑ | ↑↑ | – | Li et al. (2008) |
| Scl-Ab | ↑↑ | ↑↑ | ↓/– | Ke et al. (2012) |
| Sost transgenic | ↓ | ↓ | – | Ke et al. (2012) |
| Scl overexpression | ↓ | – | – | Zhang et al. (2016), Kim et al. (2017a) |

Table 1 Summary of bone tissue-level outcomes associated with sclerostin intervention in rodent models.

The column titled ‘Bone mass’ refers to trabecular BV/TV in the axial (spine) or appendicular (tibia or femur) skeleton. The column titled ‘Bone formation’ refers to serum bone turnover markers indicative of bone formation. The column titled ‘Bone resorption’ refers to serum bone turnover markers indicative of bone resorption. The symbols ↑ or ↓ indicate an increase, or decrease, in this parameter, respectively, and the number of arrows reflecting the size of the effect; – indicates no change in this parameter.

NR, not reported.
osteoblastogenesis and suppression of, or no effect on, osteoclast formation (depending on the antibody used). Interestingly, treatment with Scl-Ab does not appear to directly affect MM cells either in vitro or in vivo (Eda et al. 2016, Delgado-Calle et al. 2017, McDonald et al. 2017).

**Future horizons**

The discovery of causative mutations in the SOST gene in patients with sclerosteosis identified sclerostin as a ‘gem from the genome’ with a critical role in bone homeostasis (Paszty et al. 2010). Significant advances have been made in understanding the expression, biochemical and structural features of sclerostin. There are aspects of the biochemistry of this small secreted glycoprotein, which lend themselves to further investigation, for example, the biological relevance of sclerostin glycosylation, and definition of the epitope(s) through which sclerostin binds LRP4. The discovery that this protein acts as an inhibitor of the canonical WNT signalling cascade illuminated the way it regulates bone metabolism, indicating that sclerostin plays a critical role in controlling bone formation and may play an indirect role in stimulating bone resorption. Thus, pharmacological inhibition of sclerostin with Scl-Ab increases bone formation and decreases bone resorption, leading to increased bone mass and strength. However, questions remain. The relationship between circulating sclerostin and bone formation is not simple and the significance of systemic sclerostin on skeletal homeostasis is far from clear, hence further exploration of this topic is required. Although it is expressed in vascular smooth muscle cells within the aorta, the absence or inhibition of sclerostin in preclinical studies has not been linked to changes in vascular calcification and sclerostin’s role in the vasculature is not well understood. As discussed in a recent review (Appelman-Dijkstra 2018), the imbalance in serious adjudicated cardiovascular events that was observed in one of two large phase III studies with Scl-Ab in postmenopausal women with osteoporosis (Cosman et al. 2016, Saag et al. 2017) highlights the need to better understand the role of sclerostin in the vascular system.

In addition to providing structural support for the body and protection for internal organs, the skeleton is now known to influence other complex biological processes, including regulation of energy metabolism. The emerging role of sclerostin as a regulator of adipose depots points towards the existence of additional biological axes for sclerostin. In contrast to the local function of sclerostin as an inhibitor of bone formation, new findings in rodent models suggest two additional roles for sclerostin: as a local regulator of MSC fate which promotes bone marrow adipose, and as an osteocyte-secreted endocrine molecule, linking the bone with anatomically distant adipose tissue. The translation to human is currently unknown and further studies are required to more completely elucidate the bone-adipose relationship(s) and their contribution to bone mass and strength. Finally, new investigations into the role of sclerostin in multiple myeloma bone disease have suggested that sclerostin inhibition could be beneficial in this setting and have provided a platform for further studies.

---

**Declaration of interest**

All authors have been employees of UCB Pharma and may hold UCB Pharma shares and/or stock options.

**Funding**

This work did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

**Acknowledgements**

The authors thank the romosozumab teams at UCB Pharma and Amgen Inc. for their support.

**References**


Appelman-Dijkstra NM & Papapoulos SE 2018 Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway. Nature Reviews Endocrinology Epub. (https://doi.org/10.1038/s41574-018-0087-0)


bone density in sclerostosis is due to the deficiency of a novel secreted protein (SOST). *Human Molecular Genetics* **10** 537–543. (https://doi.org/10.1093/hmg/10.5.537)


Collette NM, Vee CS, Hum NR, Munugesh DK, Christiansen BA, Xie L, Economides AN, Manilay J0, Robling AG & Loos GG 2016 Sostdc1 deficiency accelerates fracture healing by promoting the expansion of periosteal mesenchymal stem cells. *Bone* **88** 20–30. (https://doi.org/10.1016/j.bone.2016.04.005)


Hardouin P, Bharass T & Lucas S 2016 Bone marrow adipose tissue: to be or not to be a typical adipose tissue? Frontiers in Endocrinology 7:85. (https://doi.org/10.3389/fendo.2016.00085)


Khe HZ, Richards WG, Li X & Ominsky MS 2012 Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocrine Reviews 33:747–783. (https://doi.org/10.1210/er.2011-1060)


Semenov MV & He X 2006 LRPs mutations linked to high bone mass diseases cause reduced LRPS binding and inhibition by SOST. *Journal of Biological Chemistry* **281** 38276–38284. (https://doi.org/10.1074/jbc.M609509200)


Received in final form 25 September 2018
Accepted 17 October 2018